$0.91
3.20% today
Nasdaq, Aug 12, 04:48 pm CET
ISIN
US19249H1032
Symbol
CHRS

Coherus BioSciences, Inc. Stock price

$0.88
+0.00 0.03% 1M
-0.23 20.69% 6M
-0.50 36.21% YTD
-0.58 39.71% 1Y
-11.77 93.04% 3Y
-17.88 95.31% 5Y
-32.27 97.34% 10Y
-11.73 93.02% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.06 7.24%
ISIN
US19249H1032
Symbol
CHRS
Industry

Key metrics

Basic
Market capitalization
$102.3m
Enterprise Value
$314.8m
Net debt
$212.5m
Cash
$82.4m
Shares outstanding
115.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.5 | 2.3
EV/Sales
1.6 | 7.0
EV/FCF
629.6
P/B
negative
Financial Health
Equity Ratio
-29.4%
Return on Equity
-21.6%
ROCE
-89.9%
ROIC
-47.1%
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$197.5m | $44.8m
EBITDA
$-99.5m | $-147.6m
EBIT
$-104.3m | $-157.5m
Net Income
$-130.9m | $-134.0m
Free Cash Flow
$500.0k
Growth (TTM | estimate)
Revenue
-34.6% | -83.2%
EBITDA
39.0% | -58.9%
EBIT
37.7% | -60.4%
Net Income
-120.9% | -570.0%
Free Cash Flow
100.3%
Margin (TTM | estimate)
Gross
56.7%
EBITDA
-50.4% | -329.9%
EBIT
-52.8%
Net
-66.3% | -299.4%
Free Cash Flow
0.3%
More
EPS
$-1.1
FCF per Share
$0.0
Short interest
28.0%
Employees
228
Rev per Employee
$1.2m
Show more

Is Coherus BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Coherus BioSciences, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
198 198
35% 35%
100%
- Direct Costs 86 86
52% 52%
43%
112 112
11% 11%
57%
- Selling and Administrative Expenses 131 131
31% 31%
66%
- Research and Development Expense 89 89
14% 14%
45%
-99 -99
39% 39%
-50%
- Depreciation and Amortization 4.82 4.82
10% 10%
2%
EBIT (Operating Income) EBIT -104 -104
38% 38%
-53%
Net Profit -131 -131
121% 121%
-66%

In millions USD.

Don't miss a Thing! We will send you all news about Coherus BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coherus BioSciences, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.
Positive
The Motley Fool
5 days ago
Coherus (CHRS) Q2 Revenue Jumps 10%
Neutral
GlobeNewsWire
5 days ago
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.
More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Denny Lanfear
Employees 228
Founded 2010
Website www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today